Pyrimidine Compound Design for HER2 Inhibition and Brain Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HER2 inhibitors, such as Lapatinib and Neratinib, have limited brain penetration due to being substrates of p-gp or Bcrp, resulting in inadequate effects against brain metastatic cancer, and there is a lack of therapeutic methods for HER2ex20ins mutation in lung cancer.
Innovation Solution
A novel pyrimidine compound with a pyrrolo[2,3-d]pyrimidine basic skeleton, substituted at position 5 with carboxamide and position 6 with alkyne, and featuring a pyrrolidine group substituted with acrylamide at position 7, which exhibits HER2 inhibitory activity and improved brain penetration properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HER2 inhibitors (Lapatinib, Neratinib) are used, then HER2 inhibitory activity is achieved, but brain penetration is limited due to being substrates of p-gp or Bcrp
Solution Approach 1:
The patent modifies molecular parameters of the HER2 inhibitor by designing a specific chemical structure (Formula I) with particular substituents and molecular weight characteristics. This structural optimization changes the compound's interaction with transport proteins, reducing substrate affinity for p-gp and Bcrp while maintaining HER2 binding capability, thereby achieving improved brain penetration without sacrificing target inhibition.
Solution Approach 2:
The invention creates a composite molecular structure combining specific functional groups (pyridine ring, substituted phenyl groups, heterocyclic moieties) in a defined architectural arrangement. This composite structure achieves dual functionality: maintaining high HER2 kinase inhibition while incorporating molecular features that evade efflux transporter recognition, effectively resolving the contradiction between target specificity and tissue penetration.
2Reliability
If HER2 inhibitors are designed for high HER2 inhibition, then antitumor effects are improved, but therapeutic methods for HER2ex20ins mutation remain lacking
Solution Approach 1:
The patent designs a universal HER2 inhibitor with broad spectrum activity that effectively targets multiple HER2 configurations including wild-type, mutated, and exon 20 insertion variants. The molecular structure (Formula I) incorporates flexible binding interactions that can accommodate various HER2 conformational states, enabling a single compound to provide multi-functional inhibition across different mutation types while maintaining potent antitumor effects.
3Object-affected harmful factors
If a novel pyrimidine compound structure is designed, then brain penetration properties are improved, but compound complexity increases
Solution Approach 1:
The patent applies local quality optimization by strategically placing specific functional groups and substituents at particular positions within the pyrimidine core structure. Rather than uniformly complicating the entire molecule, the design introduces targeted local modifications (specific heterocyclic substituents, defined alkyl/alkenyl chains at specific positions) that locally enhance brain penetration capability through reduced transporter recognition, while the overall molecular framework remains relatively streamlined and synthetically accessible.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided are a novel pyrimidine compound that inhibits HER2 activity and exhibits brain penetration properties, or a salt thereof, and a pharmaceutical composition comprising the same. A compound represented by the following formula (I), or a salt thereof: wherein R1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group; R3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s); R4 represents a hydrogen atom or a C1-C4 alkyl group; and R5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.